Linagliptin: an update of its use in patients with type 2 diabetes mellitus (Q38258278)

1 September 2017

1 reference

title

Linagliptin: an update of its use in patients with type 2 diabetes mellitus (English)

1 reference

1 September 2017

1 reference

1 reference

1

Kate McKeage

1 reference

1 September 2017

1 October 2014

1 reference

1 September 2017

1 reference

1 September 2017

74

1 reference

1 September 2017

1927-1946

1 reference

1 September 2017

16

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0308-3

1 September 2017

0 references

cites work

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

The role of gut hormones in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin: in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Liver glycogen loading dampens glycogen synthesis seen in response to either hyperinsulinemia or intraportal glucose infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0308-3

21 January 2018

Nephropathy in diabetes

1 reference

12 December 2020

Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow

1 reference

12 December 2020

The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor

1 reference

12 December 2020

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats

1 reference

12 December 2020

Standards of medical care in diabetes--2012

1 reference

12 December 2020

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensi

1 reference

12 December 2020

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

1 reference

12 December 2020

Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk

1 reference

12 December 2020

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

1 reference

12 December 2020

Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes

1 reference

12 December 2020

Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.

1 reference

12 December 2020

Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.

1 reference

12 December 2020

10.1007/S40265-014-0308-3

Identifiers

DOI

1 reference

PubMed ID

25297911

Dimensions Publication ID

1 September 2017

0 references

1 reference

PubMed ID

25297911